Mengzhu Xue

Major in Cheminformatics, System Biology and Network Biology

Experience:

2010-2013 Ph D Student in East China University of Sci. & Tech.

2007-2010 MD in Shanghai Institute of Material Medica

2003-2007 BD in Wuhan University


Research topics:

  1. Designing inhibitors of RSK2 kinase;

  2. Systems Biology study on RSK2 signaling transduction;

  3. Systems Biology study on AAnetwork with inhibitors;

  4. The analysis of the Drugbank withdrawn drugs-target network and the approved drugs-target network.

Publications:

1. Lu, W. Q. Liu, X. F. Cao, X. W. Xue, M. Z. Liu, K. D. Zhao, Z. J. Shen, X. Jiang, H. L. Xu, Y. F. Huang, J. Li, H. L. SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration. J.Med.Chem. 2011(54): 3564-3574 

2. Xue, M. Z*. Xu, M. H.* Lu, W. Q.* Huang, J. Li, H. L. Xu, Y. F. Liu, X. F. Zhao, Z. J. Synthesis, activity evaluation, and docking analysis of barbituric acid aryl hydrazone derivatives as RSK2 inhibitors. J. Enzyme. Inhib. Med. Chem. 2012. 05. (on line) DOI: 10.3109/14756366.2012.681651 (*co-authors) 

3. Xue, M. Z. Cao, X. W. Zhong, Y. Kuang, D. Liu, X. F. Zhao, Z. J. Li, H. L. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives. Curr. Pharm. Design 2012(18): 2901-2913

 4. Xue, M. Z. Yuan, J. Wu, B. Zhao, X. Liu, X. F. Huang, J. Zhao, Z. J. Li, H. L. Novel inhibitors for p90 ribosomal S6 protein kinase 2: design, synthesis and SAR. J. Chin. Pharm. Sci. 2012(21): 401-408

5. Zhong,Y. Xue, M. Z. Zhao, X. Yuan, J. Liu, X. F. Huang, J. Zhao, Z. J. Li, H. L. Xu. Y.F. Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure–activity relationship analysis. Bioorg. Med. Chem. 2013(21):1724-1734

6. Xue, M. Z. Zhang, S. D. Cai, C.Q. Yu, X. J. Shan, L. Liu, X. F. Zhang, W. D. Li, H. L. Predicting the Drug Safety for Traditional Chinese Medicine through a Comparative Analysis of Withdrawn Drugs Using Pharmacological Network. Evid. Based Compl. Alt. Med. 2013. 04 (on line) DOI: 10.1155/2013/256782

Presentations:

1. Xue, M. Z. Liu, X. F. Li, H. L. The development and application of a novel approach SHAFTS for 3D molecular similarity calculation. (Poster), Chinese Medicinal Chemistry Symposium Guangzhou, China, November 2011 

2. Xue, M. Z. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy:advances and perspectives. (Talk), the 10th Anunual symposium in the School of Pharmacy, East China University of Science and Technology, Shanghai, China, November 2012

User Login


Database


PTID

Contact us


Honglin Li's Lab
Shanghai Key Laboratory of New Drug Design
School of Pharmacy
East China University of Sci. & Tech.
Room 527, Building 18, 130 Meilong Road,
Shanghai, 200237, P. R. China
Tel: (86) 21 6425 0213
Prof. Honglin Li
hlli@ecust.edu.cn

Copyright © 2019 Prof. HongLin Li's Group, School of Pharmacy, East China University of Science & Technology · All Right Reserved.
沪ICP备19004698号-1 |  沪公网安备31011302004713号